<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00383890</url>
  </required_header>
  <id_info>
    <org_study_id>2005-006</org_study_id>
    <nct_id>NCT00383890</nct_id>
    <nct_alias>NCT00411775</nct_alias>
  </id_info>
  <brief_title>A Safety and Efficacy Study of Dexmedetomidine in Patients Requiring Sedation for Elective Awake Fiberoptic Intubation</brief_title>
  <official_title>A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Dexmedetomidine Used for Sedation During Elective Awake Fiberoptic Intubation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospira, now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospira, now a wholly owned subsidiary of Pfizer</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of dexmedetomidine versus&#xD;
      placebo used for sedation during elective awake fiberoptic intubation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An awake fiberoptic intubation is indicated for any patient with an anticipated difficult&#xD;
      airway because of their anatomy, airway trauma, morbid obesity, or unstable cervical spine&#xD;
      injuries. An awake fiberoptic intubation in a non-sedated patient can be extremely&#xD;
      stimulating, uncomfortable, and unpleasant. The clinician must focus on maintaining&#xD;
      spontaneous breathing, hemodynamic stability, and the patient's comfort. The term &quot;awake&quot;&#xD;
      fiberoptic intubation is used to distinguish this procedure from fiberoptic intubations&#xD;
      performed under general anesthesia. Although patients may be sedated for &quot;awake&quot; fiberoptic&#xD;
      intubation, they need to be responsive and capable of maintaining their own airway without&#xD;
      assistance. Vital components of a successful awake fiberoptic intubation include an&#xD;
      anesthesiologist experienced in this technique, adequate topicalization of the airway, and a&#xD;
      sedated yet cooperative subject.&#xD;
&#xD;
      Benzodiazepines, combined with opioid, are commonly used for anxiolysis and/or analgesia&#xD;
      during awake fiberoptic intubations.&#xD;
&#xD;
      Dexmedetomidine has sympatholytic, sedative, analgesic, and anxiolytic effects that attenuate&#xD;
      the catecholamine response to perioperative stress. Dexmedetomidine sedates patients by&#xD;
      decreasing sympathetic activity and the level of arousal. Further more, dexmedetomidine has&#xD;
      been found to facilitate a decrease in salivary secretion, a desirable effect during&#xD;
      fiberoptic intubations.&#xD;
&#xD;
      An estimated 100 subjects (50 DEX, 50 PBO) scheduled for an elective awake fiberoptic&#xD;
      intubation because of a potentially difficult airway will be randomized prior to intubation&#xD;
      at approximately 18 investigative sites.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2006</start_date>
  <completion_date type="Actual">March 2007</completion_date>
  <primary_completion_date type="Actual">January 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The percentage of subjects requiring rescue midazolam to achieve and/or maintain proper sedation levels throughout the study drug infusion</measure>
    <time_frame>At baseline and 15 minutes after starting study drug (prior to topicalization), and every 3 minutes thereafter throughout study drug infusion, at the end of topicalization, and prior to administration of any rescue medication.</time_frame>
    <description>Sedation levels (Ramsay Sedation Scale [RSS] score ≥2 [Patient is cooperative, oriented and tranquil])</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total dose of rescue midazolam required to achieve and/or maintain target sedation levels</measure>
    <time_frame>During the drug maintenance (i.e, Approximately 15 minutes after starting study drug).</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects requiring additional rescue medications other than midazolam to achieve and/or maintain target sedation levels</measure>
    <time_frame>During the drug maintenance (i.e, Approximately 15 minutes after starting study drug).</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anesthesiologist assessment of ease of subject care</measure>
    <time_frame>Immediately following discontinuation of study drug, prior to the scheduled surgery/procedure (Approximately 24 hours).</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject recall and satisfaction assessed 24 hours post study drug</measure>
    <time_frame>At the end of the 24-Hour Follow-Up Period</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">124</enrollment>
  <condition>Awake Fiberoptic Intubation</condition>
  <arm_group>
    <arm_group_label>Dexmedetomidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dexmedetomidine 1 mcg/kg load for 10 minutes and Dexmedetomidine Maintenance (0.7 mcg/kg/hr) for 15 min</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (PBO)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo load for 10 min and Placebo maintenance for 15 min</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine HCL Injection</intervention_name>
    <arm_group_label>Dexmedetomidine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo (PBO)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adult (≥18 years of age);&#xD;
&#xD;
          2. American Society of Anesthesiologists (ASA) score I - IV inclusive;&#xD;
&#xD;
          3. Male or female. If female, subject is non-lactating and is either:&#xD;
&#xD;
               1. Not of childbearing potential, defined as post-menopausal for at least 1 year or&#xD;
                  surgically sterile due to bilateral tubal ligation, bilateral oophorectomy or&#xD;
                  hysterectomy.&#xD;
&#xD;
               2. Of childbearing potential but is not pregnant at time of baseline and is&#xD;
                  practicing one of the following methods of birth control: oral or parenteral&#xD;
                  contraceptives, double-barrier method, vasectomized partner, or abstinence from&#xD;
                  sexual intercourse.&#xD;
&#xD;
          4. Requiring awake fiberoptic (oral or nasal) intubation because of anticipated difficult&#xD;
             airway. Subjects must meet at least one of the criteria listed below:&#xD;
&#xD;
             Criteria for Assessing Difficult Airways&#xD;
&#xD;
             i. History of difficult intubation&#xD;
&#xD;
             ii. Anticipated difficult airway&#xD;
&#xD;
               1. Prominent protruding teeth&#xD;
&#xD;
               2. Small mouth opening&#xD;
&#xD;
               3. Narrow mandible&#xD;
&#xD;
               4. Micrognathia&#xD;
&#xD;
               5. Macroglossia&#xD;
&#xD;
               6. Short, muscular neck&#xD;
&#xD;
               7. Very long neck&#xD;
&#xD;
               8. Limited neck extension&#xD;
&#xD;
               9. Congenital airway anomalies&#xD;
&#xD;
              10. Obesity&#xD;
&#xD;
              11. Known airway pathology&#xD;
&#xD;
              12. Known airway malignancy&#xD;
&#xD;
              13. Upper airway obstruction&#xD;
&#xD;
             iii. Trauma&#xD;
&#xD;
               1. Face&#xD;
&#xD;
               2. Upper airway&#xD;
&#xD;
               3. Cervical spine&#xD;
&#xD;
             iv. Anticipated difficult mask ventilation&#xD;
&#xD;
             v. Severe risk of aspiration&#xD;
&#xD;
             vi. Respiratory failure&#xD;
&#xD;
             vii. Severe hemodynamic instability&#xD;
&#xD;
          5. Subject (or subject's legally authorized representative) must voluntarily sign and&#xD;
             date the informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previous exposure to any experimental drug within 30 days prior to study drug&#xD;
             administration;&#xD;
&#xD;
          2. Central nervous system (CNS) disease with an anticipated increased intracranial&#xD;
             pressure or cerebrospinal fluid (CSF) leak;&#xD;
&#xD;
          3. Uncontrolled seizure disorder and/or known psychiatric illness that could confound a&#xD;
             normal response to sedative treatment;&#xD;
&#xD;
          4. Presence of acute alcohol intoxication;&#xD;
&#xD;
          5. Current (within 14 days of study entry) treatment with an α2-agonist or antagonist;&#xD;
&#xD;
          6. Subject for whom benzodiazepines, dexmedetomidine or other α2-agonists are&#xD;
             contraindicated;&#xD;
&#xD;
          7. Subject received an IV or oral (PO) opioid within one hour or intramuscularly within&#xD;
             four hours of the start of study drug administration;&#xD;
&#xD;
          8. Subject has acute unstable angina, laboratory confirmed acute myocardial infarction&#xD;
             within the past 6 weeks, heart rate &lt;50 bpm, systolic blood pressure (SBP) &lt;90 mmHg,&#xD;
             or complete heart block unless they have a pacemaker.&#xD;
&#xD;
          9. Subject has elevated serum glutamic pyruvate aminotransferase/alanine transaminase&#xD;
             (SGPT/ALT) and/or Serum glutamic oxaloacetic transaminase/ aspartate aminotransferase&#xD;
             (SGOT/AST) values of ≥2 times the upper limit of normal (ULN).&#xD;
&#xD;
         10. Subject has any other condition or factor which, in the Investigator's opinion, might&#xD;
             increase the risk to the subject.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Loma Linda University Medical Center</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92354</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami Jackson Memorial Hospital</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Illinois Medical Center at Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Mount Sinai School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ohio State University Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210-1228</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lehigh Valley Hospital</name>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <zip>18103-6296</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA North Texas Health Care System</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Texas Medical School at Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Texas</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scott and White Memorial Hospital</name>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <zip>76508</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Medical Center</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53295</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <study_first_submitted>October 2, 2006</study_first_submitted>
  <study_first_submitted_qc>October 2, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 4, 2006</study_first_posted>
  <last_update_submitted>July 23, 2015</last_update_submitted>
  <last_update_submitted_qc>July 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 24, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>American Society of Anesthesiologists (ASA)</keyword>
  <keyword>Mallampati Score</keyword>
  <keyword>Ramsay Sedation Scale (RSS)</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

